As a result of this acquisition, MGI Pharma becomes a wholly-owned subsidiary of Eisai Corporation of North America.
At the effective time of the merger, all outstanding shares of MGI Pharma common stock not validly tendered and accepted for payment in the tender offer were converted into the right to receive $41 per share in cash (the same price paid in the tender offer), without interest and subject to applicable withholding of taxes.